Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing 121–140 of 2532 stories
The Hospital Inpatient Services Modernization Act (S 2237) has been read twice and referred to the Committee on Finance for further consideration. This bill aims to modernize hospital inpatient services, potentially impacting healthcare delivery.
The Senate has placed S 2587, the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act for 2026, on the legislative calendar. This bill is part of the ongoing budgetary process impacting health policy funding.
The REAL Health Providers Act (HR 5281) has been referred to the Committee on Ways and Means and the Committee on Energy and Commerce for further consideration. This bill aims to address provisions related to healthcare providers, though specific details on its impact are yet to be determined.
The HR 5304 bill has been placed on the Union Calendar, indicating its progression through Congress. This bill pertains to appropriations for the Departments of Labor, Health and Human Services, and Education for the fiscal year 2026.
Policy strategist Kristi Martin highlights the need for reform of the Orphan Drug Act in light of modern drug pricing challenges. She emphasizes the importance of rethinking incentives and eligibility criteria for orphan drugs, particularly in oncology, to ensure equitable access while maintaining the law's life-saving impact.
Novo Nordisk and Eli Lilly are competing in the rapidly growing obesity market, but the article argues that their approaches and products should not be directly compared. This highlights the diverse strategies within the sector as both companies seek to capture market share.
Generate Biomedicines, an AI-driven biotech startup, has filed for an IPO after raising over $800 million for its drug discovery efforts. The company is developing a potential competitor to Tezspire for asthma treatment and plans to advance another drug into clinical trials in early 2024.
Bristol Myers Squibb reported better than expected fourth quarter earnings, despite Eliquis missing market expectations and Cobenfy facing challenges in uptake. The company's overall performance indicates resilience in a competitive landscape.
Veradermics has successfully raised $256 million in an upsized IPO, reflecting strong investor interest in its oral minoxidil therapy for hair loss. The company's shares surged over 120% on their first trading day, indicating robust market confidence in its lead program, often referred to as 'oral Rogaine'.
Veradermics successfully raised $256.3 million in its IPO, selling over 15 million shares at $17 each. This oversubscribed debut positions the company to capitalize on the growing market for treatments targeting pattern hair loss.
The FDA has initiated a new approach to support the transition from artificial petroleum-based colors to natural alternatives in the food supply. This move aims to enhance consumer safety and transparency regarding food ingredients.
Eikon has completed the largest IPO since 2024, signaling potential recovery in the biopharma sector. Analysts are monitoring other companies preparing to enter public markets this year.
EURORDIS invites applications for its European Regional Task Force on Rare Diseases, aiming to enhance collaboration and advocacy efforts across Europe. This initiative seeks to engage stakeholders in addressing the challenges faced by rare disease communities.
Novartis has cut six early-stage cancer candidates while adding two to refine its oncology strategy. CEO Vas Narasimhan emphasized ongoing investment in the early-stage pipeline and a focus on deals under $2 billion.
PrimeGen is set to go public via a SPAC deal valued at $1.5 billion, providing necessary capital to advance its pre-clinical triple-activated mesenchymal stem cell pipeline. This move positions PrimeGen to accelerate its clinical development efforts.
Eli Lilly has decided to discontinue three therapies, including a gene therapy for dementia acquired through its $1.04 billion purchase of Prevail Therapeutics. This move aligns with Lilly's strategy to focus on its GLP-1 pipeline.
Emerging platforms like circular and logic circuit RNA are expanding therapeutic possibilities in the post-COVID landscape, according to insights from industry leaders at Circio and Strand Therapeutics. This discussion highlights the innovative approaches shaping the future of RNA technology.
Pharma Times discusses the evolving landscape of customer relationships in biopharma, emphasizing the need for enhanced engagement strategies. The article highlights innovative approaches to connect with patients and stakeholders.
Pharma Times highlights the shift towards patient-centric oncology trials, emphasizing the use of data-driven insights to enhance cancer care. This approach aims to improve patient outcomes by integrating their experiences and preferences into trial designs.
Biopharma companies are increasingly open to hiring remote workers, as highlighted in the latest BioSpace employment outlook report. This shift indicates a broader trend towards flexible recruitment strategies, allowing access to a wider talent pool.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.